Antithrombotics and anticoagulants in coronary syndromes and stroke

Seminars in Thrombosis and Hemostasis

Volumn 26, Issue 3 SUPPL. 1, 2000, Pages 79-83

  Turpie, A G G ^a  

^a HHSC General Division   (Canada)

Author keywords

Acute ischemic syndrome; Low molecular weight heparin; Stroke

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; DALTEPARIN; DANAPAROID; ENOXAPARIN; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; NADROPARIN; PLACEBO; TINZAPARIN;

ANTICOAGULATION; BLEEDING; CLINICAL TRIAL; COMPARATIVE STUDY; CONFERENCE PAPER; DRUG EFFICACY; DRUG SAFETY; HEART MUSCLE ISCHEMIA; HUMAN; META ANALYSIS; PRIORITY JOURNAL; Q WAVE; STROKE;

ANTICOAGULANTS; CARDIOVASCULAR DISEASES; CEREBROVASCULAR ACCIDENT; CORONARY DISEASE; FIBRINOLYTIC AGENTS; HEMATOLOGIC AGENTS; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; PRACTICE GUIDELINES;

EID: 0033821369     PISSN: 00946176     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (25)

1. Medical progress: Unstable angina pectoris
2. Opinions regarding the diagnosis and management of venous thromboembolic disease ACCP. Consensus Committee on Pulmonary Embolism
3. Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration
4. Anticoagulants in acute coronary syndromes
5. Antiplatelet treatment with ticlopidine in unstable angina. A controlled multicenter clinical trial. The Studio della Ticlopidina nell' Angina Instabile Group
6. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE)
7. Aspirin versus heparin to prevent myocardial infarction during the acute phase of unstable angina
8. Clinical potential of antithrombotic drugs in coronary syndromes
9. Aspirin, heparin, or both to treat acute unstable angina
10. Risk of myocardial infarction and death during treatment with low dose aspirin and intravenous heparin in men with unstable coronary artery disease The RISC Group
11. Combination antithromboric therapy in unstable rest angina and non-Q-wave infarction in nonprior aspirin users. Primary end points analysis from the ATACS trial. Antithrombotic Therapy in Acute Coronary Syndromes Research Group
12. Rationale for the management of coronary syndromes with low-molecular-weight heparins
13. Low-molecular-weight heparin during instability in coronary artery disease
14. Long-term low-molecular-weight heparin (Fragmin) and/or early revascularization during instability in coronary artery disease (the FRISC II Study)
15. Comparison of low-molecular-weight heparin with unfractionated heparin acutely and with placebo for 6 weeks in the management of unstable coronary artery disease. Fragmin in unstable coronary artery disease study
16. A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group
17. One-year follow-up of the ESSENCE trial (enoxaparin versus heparin in unstable angina and non-Q-wave myocardial infarction)
18. Comparison of two treatment durations (6 days and 14 days) of a low molecular weight heparin with a 6-day treatment of unfractionated heparin in the initial management of unstable angina or non-Q wave myocardial infarction: FRAX.I.S. (FRAxiparine in Ischaemic Syndrome)
19. Invasive compared with non-invasive treatment in unstable coronary-artery disease: FRISC II prospective randomised multicentre study
20. Enoxaparin prevents death and cardiac ischemic events in unstable angina]non-Q-wave myocardial infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI) 1 IB trial
21. The International Stroke Trial (IST): A randomised trial of aspirin, subcutaneous heparin, both, or neither among 19435 patients with acute ischaemic stroke
22. CAST: Randomised placebo-controlled trial of early aspirin use in 20,000 patients with acute ischaemic stroke
23. Low molecular weight heparinoidm, ORG 10172 (danaparoid), and outcome after acute ischemic stroke: A randomized controlled trial. The Publications Committee for the Trial of ORG 10172 in Acute Stroke Treatment (TOAST) Investigators
24. Low-molecular-weight heparin for the treatment of acute ischemic stroke
25. Fraxiparine in Ischaemic Stroke Study (FISS bis)